FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200212597> ?p ?o ?g. }

• W4200212597 endingPage "47" @default.
• W4200212597 startingPage "34" @default.
• W4200212597 abstract "Anti‑NMDA encephalitis is a rare autoimmune disease of the central nervous system caused by the synthesis of autoantibodies to the NR1/NR2 subunits of the NMDA receptor, characterized by the development of acute mental, cognitive, motor, autonomic disorders, epileptic syndrome and central hypoventilation.The article presents a three‑year observation of patient 34 years old with anti‑NMDA ncephalitis associated with late‑ stage ovarian teratoma, accompanied by an increase titer of antibodies to NMDA receptors in serum to 1:640.Based on a detailed analysis of clinical, neurological, neuropsychological (MMSE, MoСA, FAB, 10 words test A.R. Luria) and laboratory‑instrumental characteristics of the disease (titer anti‑NMDA, level of IgG, IgM, IgA, lymphocyte subpopulations, EEG, MRI of the brain, pelvis) suggested a combination scheme of first and second line therapy. The sequential use of two cycles of medium‑volume membrane plasmapheresis (25–30 % of the circulating plasma volume, No. 5 + 5) was carried out in combination with pulse therapy with methylprednisolone 1.0 (No. 4 + 3) and cyclophasphamide 1.0 (No. 2 + 1) on background of persistent ovarian teratoma. Symptom regression was achieved by the end of the first cycle, and full recovery to the initial level of cognitive functions occurred after the second cycle, while maintaining the anti‑NMDA antibody titer to 1:160. After removal of ovarian teratoma, the level of anti‑NMDA decreased in a month to 1:40, and after 7 months it reached normal values (<1:10) against the background of basic pill therapy with methotrexate 12.5 mg/week.Thus, a rational combination and sequence of first and second line therapy and therapeutic apheresis, taking into account the pathogenetic features of each phase of the disease, can quickly achieve complete stable remission in patient with anti‑NMDA encephalitis." @default.
• W4200212597 created "2021-12-31" @default.
• W4200212597 creator A5002144428 @default.
• W4200212597 creator A5023533098 @default.
• W4200212597 creator A5025978382 @default.
• W4200212597 creator A5035509440 @default.
• W4200212597 creator A5041394557 @default.
• W4200212597 creator A5047890780 @default.
• W4200212597 creator A5052310555 @default.
• W4200212597 creator A5057780388 @default.
• W4200212597 creator A5060376662 @default.
• W4200212597 creator A5078110125 @default.
• W4200212597 creator A5082156125 @default.
• W4200212597 creator A5087180875 @default.
• W4200212597 date "2021-12-29" @default.
• W4200212597 modified "2023-10-01" @default.
• W4200212597 title "Therapeutic apheresis in the complex pathogenetic therapy of anti-NMDA encephalitis associated with ovarian teratoma at a late stage of the disease" @default.
• W4200212597 cites W1685331907 @default.
• W4200212597 cites W1991977449 @default.
• W4200212597 cites W1993719460 @default.
• W4200212597 cites W2011120133 @default.
• W4200212597 cites W2042697937 @default.
• W4200212597 cites W2043525741 @default.
• W4200212597 cites W2051552021 @default.
• W4200212597 cites W2053493035 @default.
• W4200212597 cites W2075429637 @default.
• W4200212597 cites W2082107657 @default.
• W4200212597 cites W2096422832 @default.
• W4200212597 cites W2098001563 @default.
• W4200212597 cites W2104956171 @default.
• W4200212597 cites W2114398221 @default.
• W4200212597 cites W2118067546 @default.
• W4200212597 cites W2144683025 @default.
• W4200212597 cites W2146199022 @default.
• W4200212597 cites W2149195569 @default.
• W4200212597 cites W2152630168 @default.
• W4200212597 cites W2163022996 @default.
• W4200212597 cites W2165010366 @default.
• W4200212597 cites W2270022662 @default.
• W4200212597 cites W2278831696 @default.
• W4200212597 cites W2290012694 @default.
• W4200212597 cites W2318429293 @default.
• W4200212597 cites W2404054411 @default.
• W4200212597 cites W2511427985 @default.
• W4200212597 cites W2515832988 @default.
• W4200212597 cites W2536498722 @default.
• W4200212597 cites W2575795500 @default.
• W4200212597 cites W2583829171 @default.
• W4200212597 cites W2595114075 @default.
• W4200212597 cites W2765300339 @default.
• W4200212597 cites W2766077621 @default.
• W4200212597 cites W2794950937 @default.
• W4200212597 cites W2799526301 @default.
• W4200212597 cites W2914761289 @default.
• W4200212597 cites W2921936233 @default.
• W4200212597 cites W2946177428 @default.
• W4200212597 cites W3197379625 @default.
• W4200212597 cites W7863310 @default.
• W4200212597 cites W88408294 @default.
• W4200212597 doi "https://doi.org/10.17650/2222-8721-2021-11-4-34-47" @default.
• W4200212597 hasPublicationYear "2021" @default.
• W4200212597 type Work @default.
• W4200212597 citedByCount "1" @default.
• W4200212597 countsByYear W42002125972023 @default.
• W4200212597 crossrefType "journal-article" @default.
• W4200212597 hasAuthorship W4200212597A5002144428 @default.
• W4200212597 hasAuthorship W4200212597A5023533098 @default.
• W4200212597 hasAuthorship W4200212597A5025978382 @default.
• W4200212597 hasAuthorship W4200212597A5035509440 @default.
• W4200212597 hasAuthorship W4200212597A5041394557 @default.
• W4200212597 hasAuthorship W4200212597A5047890780 @default.
• W4200212597 hasAuthorship W4200212597A5052310555 @default.
• W4200212597 hasAuthorship W4200212597A5057780388 @default.
• W4200212597 hasAuthorship W4200212597A5060376662 @default.
• W4200212597 hasAuthorship W4200212597A5078110125 @default.
• W4200212597 hasAuthorship W4200212597A5082156125 @default.
• W4200212597 hasAuthorship W4200212597A5087180875 @default.
• W4200212597 hasBestOaLocation W42002125971 @default.
• W4200212597 hasConcept C126322002 @default.
• W4200212597 hasConcept C142724271 @default.
• W4200212597 hasConcept C159654299 @default.
• W4200212597 hasConcept C170493617 @default.
• W4200212597 hasConcept C203014093 @default.
• W4200212597 hasConcept C2522874641 @default.
• W4200212597 hasConcept C2776057878 @default.
• W4200212597 hasConcept C2778842783 @default.
• W4200212597 hasConcept C2780211071 @default.
• W4200212597 hasConcept C2909158518 @default.
• W4200212597 hasConcept C67018056 @default.
• W4200212597 hasConcept C71924100 @default.
• W4200212597 hasConcept C83455156 @default.
• W4200212597 hasConceptScore W4200212597C126322002 @default.
• W4200212597 hasConceptScore W4200212597C142724271 @default.
• W4200212597 hasConceptScore W4200212597C159654299 @default.
• W4200212597 hasConceptScore W4200212597C170493617 @default.
• W4200212597 hasConceptScore W4200212597C203014093 @default.
• W4200212597 hasConceptScore W4200212597C2522874641 @default.
• W4200212597 hasConceptScore W4200212597C2776057878 @default.

• next